Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...

Since joining GE HealthCare in 2019 ... years and expanded the company’s manufacturing footprint in Beijing, Wuxi, Tianjin and Shanghai and built two new manufacturing sites in Chengdu and ...

GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, today announced that Yihao Zhang, president and CEO, China, will retire from the company effective July 1, 2025. Will Song ...

Insilico Medicine, whose Hong Kong IPO application lapsed in 2024, is still considering going public in the city, said ...

Solar Photovoltaic (PV) Systems: This segment holds the largest market share due to the significant growth in PV capacity in Vietnam. The country’s solar PV capacity surged from 86 MW in 2018 to 4,750 ...

and Wuxi; as well as establishing new sites in Shenzhen and Chengdu. "GE HealthCare announces Will Song as new president and CEO in China" was originally created and published by Medical Device ...

GE HealthCare has announced a leadership transition for its China ... and expanding the manufacturing presence in areas such as Shanghai, Tianjin, Beijing, and Wuxi; as well as establishing new sites ...

Yihao Zhang, GE HealthCare’s president and CEO for China ... Under his stewardship, the company expanded in Beijing, Wuxi, Tianjin and Shanghai and built two new manufacturing sites in Chengdu ...